ReviewNature reviews. Neuroscience2011
The neurobiology of gliomas: from cell biology to the development of therapeutic approaches.
Review in Nature reviews. Neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
154 citing papers in PubMed, 3 syntheses or guidelines pooled it, 285 citations in OpenAlex.
- A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art.Frontiers in oncology · 2022Pooled it
- PAMAM Dendrimer Nanomolecules Utilized as Drug Delivery Systems for Potential Treatment of Glioblastoma: A Systematic Review.International journal of nanomedicine · 2020Pooled it
- Quantitative assessment of the association between XRCC3 C18607T polymorphism and glioma risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.Acta neuropathologica communications · 2018Trial
- Prognostic Value of Conventional Magnetic Resonance Imaging for Adult Patients with Brain Tumors.Clinical neuroradiology · 2015Trial
- Machine-Learning-Based Survival Prediction in Glioblastoma Using Graph-Theoretical Analysis of Structural Network Alterations.Cancers · 2026Article
- Development and validation of a novel glioblastoma prognostic model: identifying STOX1 and ZNF248 as ferroptosis-related biomarkers.Cancer cell international · 2025Article
- Recent Advances in Marine-Derived Nanoformulation for the Management of Glioblastoma.Molecular biotechnology · 2025Review
- Artificial Intelligent-Enhanced Metabolite Profiling for Intraoperative IDH1 Genotyping in Glioma Using an Orthogonally Responsive SERS Probe.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Review
- Cancer neuroscience and glioma: clinical implications.Acta neurochirurgica · 2025Review
- miR-216 Is a Key Regulator and Potential Marker in Human Cancers.Advanced biomedical research · 2025Review
- Markers of tumor-associated macrophages and microglia exhibit high intratumoral heterogeneity in human glioblastoma tissue.Oncoimmunology · 2024Article
- mMolecular neurobiology · 2024Article
- Effect of radiochemotherapy on peripheral immune response in glioblastoma.Cancer immunology, immunotherapy : CII · 2024Article
- Novel insights on genetics and epigenetics as clinical targets for paediatric astrocytoma.Clinical and translational medicine · 2024Review
- The TGF-β Family in Glioblastoma.International journal of molecular sciences · 2024Review
- Impact of endogenous viral elements on glioma clinical phenotypes by inducing OCT4 in the host.Frontiers in cellular and infection microbiology · 2024Article
- Redox Homeostasis and Beyond: The Role of Wild-Type Isocitrate Dehydrogenases for the Pathogenesis of Glioblastoma.Antioxidants & redox signaling · 2023Review
- Cystathionine gamma-lyase (CTH) inhibition attenuates glioblastoma formation.Redox biology · 2023Article
94 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are the most common type of primary brain tumour and are often fast growing with a poor prognosis for the patient. Their complex cellular composition, diffuse invasiveness and capacity to escape therapies has challenged researchers for decades and hampered progress towards an effective treatment. Recent molecular characterization of tumour cells combined with new insights into cellular diversification that occurs during development, and the modelling of these processes in transgenic animals have enabled a more detailed understanding of the events that underlie gliomagenesis. Combining this enhanced understanding of the relationship between neural stem cell biology and the cell lineage relationships of tumour cells with model systems offers new opportunities to develop specific and effective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.